A Phase 2 interventional study of CDP6038 (olokizumab) in Rheumatoid Arthritis, sponsored by UCB BIOSCIENCES, Inc.. Terminated at 55 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-14.
Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.
Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one is the 6th largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 2, and was the 3rd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4
First in 2009; this study’s year is marked. 2 started in 2011.
This study's enrollment of 190 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 206 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under UCB BIOSCIENCES, Inc., one of the names counted as UCB S.A.. Under that name alone:
UCB BIOSCIENCES, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
42 studies in Arthritis, Rheumatoid by UCB S.A.: 1 open now, 2 under way, none of them phase 3. Of 39 finished, 26 (67%) have results posted.
Among the 42 studies in Arthritis, Rheumatoid by UCB S.A., this one is the 19th largest by enrollment of the 34 interventional ones that give a count, is one of 7 that started in 2011, is one of 5 in phase 2, and was the 22nd registered.
UCB S.A.’s Arthritis, Rheumatoid studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 42 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long term safety and tolerability of CDP6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis who completed study RA0056 (NCT01242488).
Male and female subjects were randomized in a multi-center, open-label, follow-up study to assess the long-term safety and efficacy of a subcutaneous dose of 120 mg CDP6038 (olokizumab), every two weeks, for the treatment of active rheumatoid arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: CDP6038 (olokizumab)
100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
Reported TEAEs included adverse events that started or worsened after the first dose of CDP6038 (olokizumab) in Study RA0057 and within 30 days after the last dose.
Time frame: From Baseline (Week 0 of Study RA0057) until 30 days after the last dose (maximum up to 780 days)
Change From Baseline (Week 0 of Study RA0056) in the Disease Activity Score-28-joint Count (C-reactive Protein) (DAS28[CRP]) to Week 12 of Study RA0057
DAS28(CRP) was calculated using the tender/painful joint count (TJC) and swollen joint count (SJC) from 28 joints, the Patient's Global Assessment of Disease Activity (PtGADA)-Visual Analog Scale (VAS), andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.
Time frame: Baseline (Week 0 of Study RA0056) and Week 12 (Study RA0057)
Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 24 of Study RA0057
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.
Time frame: Baseline (Week 0 of Study RA0056) and Week 24 (Study RA0057)
Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 48 of Study RA0057
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.
Time frame: Baseline (Week 0 of Study RA0056) and Week 48 (Study RA0057)
Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 96 of Study RA0057
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.
Time frame: Baseline (Week 0 of Study RA0056) and Week 96 (Study RA0057)
The American College of Rheumatology (ACR) 20% (ACR20) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057
ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, Physician's Global Assessment of Disease Activity (PhGADA)-VAS, Patient's Assessment of Arthritis Pain (PAAP)-VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI) and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0056) up to Week 12 (Study RA0057)
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057
ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0056) up to Week 24 (Study RA0057)
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057
ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0056) up to Week 48 (Study RA0057)
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057
ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0056) up to Week 96 (Study RA0057)
The ACR 50% (ACR50) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057
ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0056) up to Week 12 (Study RA0057)
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057
ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0056) up to Week 24 (Study RA0057)
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057
ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0056) up to Week 48 (Study RA0057)
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057
ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0056) up to Week 96 (Study RA0057)
The ACR 70% (ACR70) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057
ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0056) up to Week 12 (Study RA0057)
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057
ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0056) up to Week 24 (Study RA0057)
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057
ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0056) up to Week 48 (Study RA0057)
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057
ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0056) up to Week 96 (Study RA0057)
Percentage of Subjects With DAS28(CRP) <2.6 at Week 12 of Study RA0057
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.
Time frame: Week 12 (Study RA0057)
Percentage of Subjects With DAS28(CRP) <2.6 at Week 24 of Study RA0057
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.
Time frame: Week 24 (Study RA0057)
Percentage of Subjects With DAS28(CRP) <2.6 at Week 48 of Study RA0057
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.
Time frame: Week 48 (Study RA0057)
Percentage of Subjects With DAS28(CRP) <2.6 at Week 96 of Study RA0057
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.
Time frame: Week 96 (Study RA0057)
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 12 of Study RA0057
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than or equal to (\<=) 3.2 implies low disease activity.
Time frame: Week 12 (Study RA0057)
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 24 of Study RA0057
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score \<=3.2 implies low disease activity.
Time frame: Week 24 (Study RA0057)
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 48 of Study RA0057
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score \<=3.2 implies low disease activity.
Time frame: Week 48 (Study RA0057)
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 96 of Study RA0057
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score \<=3.2 implies low disease activity.
Time frame: Week 96 (Study RA0057)
Change From Baseline (Week 0 of Study RA0056) in the Clinical Disease Activity Index (CDAI) to Week 48 of Study RA0057
CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity.
Time frame: Baseline (Week 0 of Study RA0056) and Week 48 (Study RA0057)
Change From Baseline (Week 0 of Study RA0056) in the CDAI to Week 96 of Study RA0057
CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity.
Time frame: Baseline (Week 0 of Study RA0056) and Week 96 (Study RA0057)
Change From Baseline (Week 0 of Study RA0056) in the Simplified Disease Activity Index (SDAI) to Week 48 of Study RA0057
SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (in milligrams per decilitre \[mg/dL\]), according to the following formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity.
Time frame: Baseline (Week 0 of Study RA0056) and Week 48 (Study RA0057)
Change From Baseline (Week 0 of Study RA0056) in the SDAI to Week 96 of Study RA0057
SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (in milligrams per decilitre \[mg/dL\]), according to the following formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity.
Time frame: Baseline (Week 0 of Study RA0056) and Week 96 (Study RA0057)
The present study was an open-label extension to study RA0056 (NCT01242488). Subjects completing the 12-week treatment period of study RA0056 had the opportunity to participate in this study. First subject enrolled: 07 March 2011. Early termination: 05 Aug 2013.
| Milestone | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Started | 20 | 20 | 21 | 20 | 17 | 16 | 40 | 36 |
| Completed | 4 | 12 | 8 | 7 | 7 | 5 | 9 | 15 |
| Not completed | 16 | 8 | 13 | 13 | 10 | 11 | 31 | 21 |
| Withdrew: Adverse event | 3 | 1 | 4 | 3 | 1 | 6 | 11 | 3 |
| Withdrew: Lack of efficacy | 1 | 4 | 1 | 1 | 1 | 0 | 2 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 2 | 0 | 4 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 2 | 2 | 1 | 1 | 1 | 2 | 1 |
| Withdrew: Study termination | 8 | 1 | 5 | 4 | 4 | 4 | 8 | 10 |
| Withdrew: Continued elevated liver enzymes | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Methotrexate discontinued | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator discretion | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Required restricted steroid injections | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Ongoing missed appointments | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Failure to comply with visits | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Patient decision due to transport | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Reported TEAEs included adverse events that started or worsened after the first dose of CDP6038 (olokizumab) in Study RA0057 and within 30 days after the last dose.
| Participants | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Treatment-emergent Adverse Events (TEAEs) | 17 | 20 | 19 | 18 | 15 | 15 | 39 | 35 |
DAS28(CRP) was calculated using the tender/painful joint count (TJC) and swollen joint count (SJC) from 28 joints, the Patient's Global Assessment of Disease Activity (PtGADA)-Visual Analog Scale (VAS), andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.
| units on a scale | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline (Week 0 of Study RA0056) in the Disease Activity Score-28-joint Count (C-reactive Protein) (DAS28[CRP]) to Week 12 of Study RA0057 | -2.2809 ± 1.45737 | -2.2485 ± 1.39384 | -2.5123 ± 1.39667 | -2.2230 ± 1.17572 | -1.6957 ± 0.67335 | -2.1735 ± 1.56606 | -2.3727 ± 1.41421 | -2.4710 ± 1.43947 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.
| units on a scale | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 24 of Study RA0057 | -2.6441 ± 1.46566 | 1.46566 ± 1.17637 | -2.5811 ± 1.40191 | -2.5999 ± 1.16812 | -1.7189 ± 0.87218 | -2.4221 ± 1.37341 | -2.1484 ± 1.34676 | -2.7624 ± 1.47841 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.
| units on a scale | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 48 of Study RA0057 | -2.3257 ± 1.07427 | -2.2498 ± 1.66580 | -2.5277 ± 1.56763 | -2.7050 ± 0.96160 | -2.3824 ± 0.79065 | -2.1501 ± 0.64141 | -2.2403 ± 1.47765 | -2.7611 ± 1.31329 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.
| units on a scale | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 96 of Study RA0057 | -3.2427 ± 1.74642 | -3.5767 | -2.5985 ± 2.16200 | -3.0999 ± 0.02877 | -1.7516 ± 2.03992 | -2.6451 ± 0.96108 | -3.3173 ± 3.23508 | -3.7982 ± 1.23889 |
ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, Physician's Global Assessment of Disease Activity (PhGADA)-VAS, Patient's Assessment of Arthritis Pain (PAAP)-VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI) and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| The American College of Rheumatology (ACR) 20% (ACR20) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057 | 40.0 | 50.0 | 76.2 | 35.0 | 58.8 | 50.0 | 47.5 | 52.8 |
ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057 | 40.0 | 50.0 | 66.7 | 30.0 | 47.1 | 62.5 | 42.5 | 63.9 |
ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057 | 40.0 | 30.0 | 42.9 | 35.0 | 47.1 | 43.8 | 25.0 | 50.0 |
ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057 | 15.0 | 5.0 | 9.5 | 5.0 | 11.8 | 12.5 | 2.5 | 13.9 |
ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| The ACR 50% (ACR50) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057 | 25.0 | 15.0 | 33.3 | 15.0 | 17.6 | 18.8 | 27.5 | 38.9 |
ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057 | 20.0 | 20.0 | 33.3 | 15.0 | 11.8 | 43.8 | 25.0 | 41.7 |
ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057 | 10.0 | 15.0 | 28.6 | 20.0 | 35.3 | 31.3 | 15.0 | 33.3 |
ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057 | 10.0 | 5.0 | 4.8 | 0.0 | 11.8 | 6.3 | 2.5 | 8.3 |
ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| The ACR 70% (ACR70) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057 | 10.0 | 5.0 | 19.0 | 5.0 | 0.0 | 18.8 | 15.0 | 13.9 |
ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057 | 10.0 | 15.0 | 19.0 | 5.0 | 0.0 | 12.5 | 10.0 | 25.0 |
ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057 | 5.0 | 5.0 | 23.8 | 10.0 | 11.8 | 6.3 | 10.0 | 13.9 |
ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057 | 5.0 | 0.0 | 4.8 | 0.0 | 5.9 | 0.0 | 2.5 | 5.6 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.
| Percentage of subjects | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Percentage of Subjects With DAS28(CRP) <2.6 at Week 12 of Study RA0057 | 25.0 | 30.0 | 38.1 | 25.0 | 0 | 18.8 | 25.0 | 25.0 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.
| Percentage of subjects | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Percentage of Subjects With DAS28(CRP) <2.6 at Week 24 of Study RA0057 | 25.0 | 35.0 | 33.3 | 25.0 | 17.6 | 12.5 | 20.0 | 33.3 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.
| Percentage of subjects | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Percentage of Subjects With DAS28(CRP) <2.6 at Week 48 of Study RA0057 | 20.0 | 30.0 | 23.8 | 20.0 | 29.4 | 12.5 | 15.0 | 22.2 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.
| Percentage of subjects | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Percentage of Subjects With DAS28(CRP) <2.6 at Week 96 of Study RA0057 | 10.0 | 5.0 | 9.5 | 5.0 | 11.8 | 0 | 2.5 | 8.3 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than or equal to (\<=) 3.2 implies low disease activity.
| Percentage of subjects | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 12 of Study RA0057 | 35.6 | 40.0 | 52.4 | 30.0 | 17.6 | 25.0 | 35.0 | 44.4 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score \<=3.2 implies low disease activity.
| Percentage of subjects | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 24 of Study RA0057 | 35.0 | 40.0 | 38.1 | 30.0 | 23.5 | 37.5 | 35.0 | 50.0 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score \<=3.2 implies low disease activity.
| Percentage of subjects | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 48 of Study RA0057 | 25.0 | 45.0 | 23.8 | 25.0 | 29.4 | 18.8 | 22.5 | 47.2 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score \<=3.2 implies low disease activity.
| Percentage of subjects | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 96 of Study RA0057 | 15.0 | 5.0 | 9.5 | 5.0 | 11.8 | 0 | 2.5 | 11.1 |
CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity.
| units on a scale | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline (Week 0 of Study RA0056) in the Clinical Disease Activity Index (CDAI) to Week 48 of Study RA0057 | -80.1000 ± 53.28425 | -65.3373 ± 63.72098 | -94.3335 ± 61.48562 | -80.8077 ± 57.91606 | -79.9231 ± 30.09849 | -84.8378 ± 33.77586 | -74.3315 ± 53.99274 | -83.4950 ± 42.48396 |
CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity.
| units on a scale | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline (Week 0 of Study RA0056) in the CDAI to Week 96 of Study RA0057 | -108.0000 ± 66.77574 | -118.0000 | -89.0000 ± 55.97321 | -74.3846 ± 4.78657 | -74.0000 ± 55.74944 | -90.5000 ± 13.43503 | -104.5000 ± 126.57211 | -107.4000 ± 51.52960 |
SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (in milligrams per decilitre \[mg/dL\]), according to the following formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity.
| units on a scale | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline (Week 0 of Study RA0056) in the Simplified Disease Activity Index (SDAI) to Week 48 of Study RA0057 | -92.1000 ± 62.22799 | -75.8757 ± 74.37825 | -104.6668 ± 80.47988 | -92.4077 ± 55.42723 | -87.7564 ± 28.41084 | -112.5378 ± 52.99896 | -87.5815 ± 59.26016 | -107.4080 ± 60.17362 |
SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (in milligrams per decilitre \[mg/dL\]), according to the following formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity.
| units on a scale | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline (Week 0 of Study RA0056) in the SDAI to Week 96 of Study RA0057 | -111.0000 ± 68.78953 | -125.0000 | -90.3333 ± 56.04760 | -91.8846 ± 29.53531 | -75.3333 ± 56.09219 | -147.5000 ± 77.07464 | -128.0000 ± 147.07821 | -143.4000 ± 80.28574 |
Collected over From Baseline (Week 0 of Study RA0057) until 30 days after the last dose (maximum up to 780 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RA0056 CDP6038 (Olokizumab) 120 mg q2w | 0/20 (0%) | 3/20 (15%) | 16/20 (80%) |
| RA0056 CDP6038 (Olokizumab) 120 mg q4w | 0/20 (0%) | 6/20 (30%) | 20/20 (100%) |
| RA0056 CDP6038 (Olokizumab) 240 mg q2w | 0/21 (0%) | 6/21 (28.6%) | 18/21 (85.7%) |
| RA0056 CDP6038 (Olokizumab) 240 mg q4w | 0/20 (0%) | 7/20 (35%) | 17/20 (85%) |
| RA0056 CDP6038 (Olokizumab) 60 mg q2w | 0/17 (0%) | 5/17 (29.4%) | 15/17 (88.2%) |
| RA0056 CDP6038 (Olokizumab) 60 mg q4w | 1/16 (6.3%) | 3/16 (18.8%) | 15/16 (93.8%) |
| RA0056 Placebo | 1/40 (2.5%) | 14/40 (35%) | 36/40 (90%) |
| RA0056 Tocilizumab 8 mg/kg q4w | 0/36 (0%) | 4/36 (11.1%) | 35/36 (97.2%) |
| Event | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Chest painGeneral disorders | 0/20 | 1/20 | 0/21 | 2/20 | 0/17 | 0/16 | 1/40 | 0/36 |
| PneumoniaInfections and infestations | 0/20 | 0/20 | 0/21 | 1/20 | 0/17 | 1/16 | 0/40 | 0/36 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/20 | 0/20 | 0/21 | 0/20 | 0/17 | 1/16 | 0/40 | 0/36 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/20 | 0/20 | 0/21 | 0/20 | 0/17 | 1/16 | 0/40 | 0/36 |
| EmphysemaRespiratory, thoracic and mediastinal disorders | 0/20 | 0/20 | 0/21 | 0/20 | 0/17 | 1/16 | 0/40 | 0/36 |
| Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 0/20 | 0/20 | 0/21 | 0/20 | 0/17 | 1/16 | 0/40 | 0/36 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/20 | 0/20 | 0/21 | 0/20 | 0/17 | 1/16 | 0/40 | 0/36 |
| CellulitisInfections and infestations | 1/20 | 0/20 | 0/21 | 0/20 | 1/17 | 0/16 | 1/40 | 0/36 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/20 | 0/20 | 0/21 | 1/20 | 1/17 | 0/16 | 0/40 | 0/36 |
| CholecystectomySurgical and medical procedures | 0/20 | 0/20 | 0/21 | 0/20 | 1/17 | 0/16 | 0/40 | 0/36 |
| Event | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w |
|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 3/20 | 3/20 | 9/21 | 2/20 | 4/17 | 3/16 | 7/40 | 5/36 |
| NasopharyngitisInfections and infestations | 1/20 | 6/20 | 0/21 | 1/20 | 2/17 | 2/16 | 3/40 | 3/36 |
| HeadacheNervous system disorders | 1/20 | 6/20 | 1/21 | 1/20 | 1/17 | 0/16 | 1/40 | 4/36 |
| Urinary tract infectionInfections and infestations | 2/20 | 1/20 | 6/21 | 2/20 | 2/17 | 3/16 | 5/40 | 5/36 |
| Back painMusculoskeletal and connective tissue disorders | 0/20 | 5/20 | 2/21 | 2/20 | 0/17 | 0/16 | 7/40 | 4/36 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/20 | 4/20 | 3/21 | 2/20 | 1/17 | 4/16 | 6/40 | 5/36 |
| RashSkin and subcutaneous tissue disorders | 5/20 | 1/20 | 2/21 | 0/20 | 1/17 | 1/16 | 1/40 | 3/36 |
| Injection site reactionGeneral disorders | 2/20 | 2/20 | 0/21 | 1/20 | 2/17 | 0/16 | 6/40 | 8/36 |
| BronchitisInfections and infestations | 1/20 | 2/20 | 3/21 | 3/20 | 1/17 | 3/16 | 5/40 | 3/36 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 3/20 | 2/20 | 1/21 | 3/20 | 1/17 | 3/16 | 3/40 | 4/36 |
Safety Population included all enrolled subjects who received at least 1 injection of CDP6038 (olokizumab) in Study RA0057.
| Age, Customized(Participants) | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 17 | 16 | 17 | 14 | 13 | 14 | 27 | 29 | 147 |
| >=65 years | 3 | 4 | 4 | 6 | 4 | 2 | 13 | 7 | 43 |
| Sex: Female, Male(Participants) | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 17 | 17 | 19 | 16 | 14 | 14 | 33 | 31 | 161 |
| Male | 3 | 3 | 2 | 4 | 3 | 2 | 7 | 5 | 29 |
| Race (NIH/OMB)(Participants) | RA0056 CDP6038 (Olokizumab) 120 mg q2w | RA0056 CDP6038 (Olokizumab) 120 mg q4w | RA0056 CDP6038 (Olokizumab) 240 mg q2w | RA0056 CDP6038 (Olokizumab) 240 mg q4w | RA0056 CDP6038 (Olokizumab) 60 mg q2w | RA0056 CDP6038 (Olokizumab) 60 mg q4w | RA0056 Placebo | RA0056 Tocilizumab 8 mg/kg q4w | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 3 | 2 | 1 | 4 | 3 | 4 | 19 |
| White | 19 | 18 | 18 | 18 | 16 | 12 | 35 | 31 | 167 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 4 |
Ran from Mar 2011 to primary completion in May 2013, 25 months.
Results were first posted in Apr 2022, 8 years 11 months after primary completion. A results delay was requested in Jun 2013.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olokizumab